PDB48 MANAGEMENT AND TREATMENT ADHERENCE IN TYPE 2 DIABETIC PATIENTS IN SPAIN  by Secnik, K et al.
A239Abstracts
(in duplicate 15-days separated to assess test-retest reliability),
trait-anxiety scale of the STAI and eight speciﬁc questions about
glycemic control, compliance and pain were administered.
Sociodemographic and clinical data were also collected. Feasi-
bility (item and questionnaire responder rate and time to com-
pletion) content validity (item-total correlation and factor
analysis), concept validity (correlation with STAI and speciﬁc
questions) and reliability (test-retest and Cronbach’s Alpha) were
assessed. RESULTS: A 32-items version was developed by an
expert panel and administered to 93 (35 Type 1, 58 Type 2)
insulin-treated diabetic patients. Ninety-nine% of patients
answered all items in 5 minutes (median). Item-total correlation
and factor analysis lead to an abridged version with 19 items,
maintaining the two original dimensions, and explaining the
47.4% of total variance: FSI; 29.5%, and FST;17.9%. Test-retest
correlation coefﬁcient were 0.85 (FSI) and 0.94 (FST); Cron-
bachxs Alpha were 0.81 (FSI) and 0.89 (FST). FST correlated
positively with time treated with insulin (p < 0.011, type 2); FSI
correlated positively with patient reported compliance (p =
0.002) and lack of worry in diabetes consequences (p = 0.005,
type 2), and negatively with time treated with insulin (p < 0.023,
type 1). CONCLUSIONS: We developed a new-recalibrated
version of the Spanish D-FISQ called MIAT-D. Feasibility,
dimensionality, content validity and reliability were accurate.
Due to the fact of cultural differences and lack of a gold stan-
dard for concept validity, this property need to be explored in
further studies.
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OBJECTIVES: Management of Spanish patients with Type 2 
diabetes and predictors of adherence to their medication.
METHODS: Multicenter, naturalistic study of type 2 diabetes
patients with a diagnosis longer than one year. Patients were con-
secutively included in the study among those attending any of
the selected 30 Primary Care Centers distributed throughout
Spain Sociodemographic and clinical variables were collected.
Patients completed the Morisky-Green questionnaire as a
measure of adherence. A logistic regression was performed with
sociodemographic, clinical, and treatment variables to predict
factors of adherence. RESULTS: A total of 294 patients were
included in the study (mean age = 67.5 yrs; mean duration of dia-
betes = 9. 9yrs). A total of 6.1% were not receiving anti-diabetic
pharmacological treatment, 70.4% received oral(s) therapy,
10.9% were in insulin therapy, and 12.6% a combination of
insulin and oral(s) therapy. A total of 58.2% of patients had poor
glycemic control (HbA1c > 6.5%). With respect to diabetic com-
plications, 20.4% of patients suffered from microvascular com-
plications only, 11.2% reported macrovascular issues only, while
14.3% suffered from both micro and macrovascular complica-
tions. The Morisky-Green questionnaire showed only 47.8% of
patients under pharmacological treatment reported a high level
of adherence. The logistic regression models showed in that in
those patients receiving only insulin, the probability of having a
high level of adherence is signiﬁcantly higher (odds ratio : 2.7)
than non-insulin receiving patients. Moreover, when a patient’s
HbA1c value is lower by one percentage point, the probability
of having a high level of adherence is greater (odds ratio : 1.3)
compared to the adherence seen at a higher A1c level. CON-
CLUSIONS: Oral agents were the most commonly prescribed
anti-diabetic pharmacological agent. Less than half of the
patients reported high adherence to their medication. The level
of diabetes control and insulin treatment were found to be asso-
ciated with adherence although further work should investigate
the causal relationship between these variables.
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OBJECTIVES: Patient reported outcomes (PRO), quality of life
(QoL) and clinical efﬁcacy achieved with a combination of
insulin glargine (GLA) and insulin glulisine (GLU) were docu-
mented in daily practice. METHODS: An observational study in
Germany documented 1447 type 1 patients (age 42.6 ± 14.5
years) and 5695 type 2 patients (age 61.8 ± 10.5 years) insufﬁ-
ciently controlled under prior intensiﬁed insulin therapy who
were switched to GLA (mean daily dose at baseline 21.8 ± 9.6
I.U. for type 1 and 24.4 ± 13.0 I.U. for type 2) and GLU (28.0
± 13.0 and 34.4 ± 23.0 I.U. respectively) for 89 and 91 days in
median respectively. Efﬁcacy was measured by fasting blood
glucose (FBG) and HbA1c values. QoL was evaluated with a 5-
item-Likert-scales from physician`s perspective. PRO was mea-
sured with a visual analogue scale (VAS) and a diabetes treatment
satisfaction questionnaire (DTSQs) respectively. RESULTS: The
ﬁndings are given for type 1 and type 2 respectively. Mean FBG
levels decreased about 36.4 ± 48.7 and 48.3 ± 41.6 mg/dl,
HbA1c-values about 1.0 ± 1.2 and 1.2 ± 1.0% compared to pre-
vious therapy. Sum scores for six categories of QoL in physician’s
assessment improved from 14.5 ± 3.6 to 10.1 ± 3.1 at follow-up
and from 15.4 ± 3.7 to 10.4 ± 3.2. VAS-scores (0 to 100 scale)
improved from 41.9 ± 22.0 to 19.6 ± 14.1 and from 49.6 ± 20.9
to 22.8 ± 16.0, DTSQs-sum scores from 20.7 ± 6.7 to 29.3 ± 5.1
and from 19.1 ± 6.6 to 28.4 ± 5.4 (p < 0.0001 for all reduc-
tions). CONCLUSION: In comparison to preceding insulin
treatment, basal-bolus therapy with GLA and GLU improved
various treatment satisfaction measures from different perspec-
tives in accordance with clinical efﬁcacy.
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OBJECTIVES: Clinical wisdom assumes that treatment satisfac-
tion (TS)with insulin improves with fewer injections and side
effects. We examined the relationships between TS, patient char-
acteristics (age, gender, ethnicity, weight, co-morbidities, diabetes
duration) and treatment outcomes (HbA1c, number of daily
injections, weight gain, hypoglycemic events).METHODS: Base-
line and 28 week RCT data comparing efﬁcacy and safety of
Biphasic Insulin Aspart 70/30 (BIAsp 70/30, NovoMix®
30/NovologMix® 70/30) vs. insulin glargine in type 2 diabet-
ics(n = 240) were analyzed. Subjects completed the Insulin Treat-
ment Satisfaction Questionnaire (ITSQ—overall TS and 5
domains: Lifestyle Flexibility, Hypoglycemic Control, Glycemic
Control, Device Satisfaction, Inconvenience of Regimen).
Regression analyses examined the relationship between TS,
patient/disease characteristic and outcomes. Signiﬁcant factors
were examined together by multivariate regression analyses.
